Compound Comparisons
Side-by-side evidence-based analysis of structurally or functionally related peptides. For research purposes only.
Semax
A synthetic ACTH fragment studied for neuroprotection and BDNF upregulation. Pharmaceutical approval in Russia for stroke recovery.
Adamax
N-Acetyl Semax Amidate — enhanced Semax derivative studied for cognitive enhancement and neuroplasticity.
Research Verdict
Semax has the stronger clinical pedigree with Russian human trial data; Adamax offers enhanced pharmacokinetics with an adamantane scaffold for potentially longer duration. Semax is the evidence-first choice; Adamax is the next-generation derivative worth monitoring.
Research Context
Both peptides originate from modification of the ACTH(4-7) fragment (Met-Glu-His-Phe). Semax appends the Pro-Gly-Pro sequence to extend metabolic stability; Adamax replaces this with an adamantane-based modification that further amplifies stability and membrane permeability. For researchers prioritizing evidence depth, Semax remains the gold standard. For those exploring pharmacokinetic optimization, Adamax represents a compelling next-generation hypothesis.
Shared Mechanisms
Semax Only
- 30+ years clinical data
- Human anxiolytic & stroke studies
- Approved in Russia (nasal spray)
- PCAC July 2026 review candidate
Adamax Only
- Adamantane scaffold (extended half-life)
- Superior predicted BBB penetration
- Next-gen derivative — limited clinical data
- Higher lipophilicity
Bio-Regulatory Compatibility Matrix
Compatibility Assessment
Low Compatibility
Analysis
Half-life data incomplete for one or both compounds — cannot assess pharmacokinetic alignment.
No receptor target data available for either compound — target-level interaction cannot be assessed.
Both compounds are linked to 1 shared research goal(s) — stacking may be complementary for that objective.
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.